Sign in
Click here - to use the wp menu builder
Sign in
Welcome!
Log into your account
your username
your password
Forgot your password?
Password recovery
Recover your password
your email
Search
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Password recovery
Recover your password
your email
A password will be e-mailed to you.
Monday, December 23, 2024
Sign in / Join
Facebook
Instagram
Twitter
Vimeo
Youtube
Pharma Deals
Update
Oncology
Search
LATEST ARTICLES
Appointments
Robert Möller Appointed to Fresenius Management Board
pharmaquotient.com
-
8 September 2023
0
Merger & Acquisition
Blackstone, Torrent Pharma in race to acquire Cipla promoter stake
pharmaquotient.com
-
1 September 2023
0
Appointments
E. Morrey Atkinson, Ph.D., Appointed as a EVP, CTO Officer Head of Biopharmaceutical Sciences and Manufacturing Operations at Vertex
pharmaquotient.com
-
29 August 2023
0
Regulatory update
Janssen files sNDA Seeking full Approval of BALVERSA® (erdafitinib) Locally Advanced or Metastatic Urothelial Carcinoma
pharmaquotient.com
-
29 August 2023
0
generic
FDA Approves Biosimilar Tyruko® for the Treatment of Relapsing Forms of Multiple Sclerosis
pharmaquotient.com
-
25 August 2023
0
Appointments
Dr. Juergen Eckhardt appointed as Bayer’s Head of Pharmaceuticals Business Development & Licensing / Open Innovation
pharmaquotient.com
-
22 August 2023
0
Appointments
Heike Prinz appointed Bayer AG’s Board of Management
pharmaquotient.com
-
21 August 2023
0
Regulatory update
Janssen Announced EU approval of TECVAYLI® with Reduced Dosing Frequency
pharmaquotient.com
-
18 August 2023
0
China
AstraZeneca announced Forxiga China Approval in Symptomatic Heart Failure Patients
pharmaquotient.com
-
18 August 2023
0
Regulatory update
Abbvie Announces EU Approval of AQUIPTA®(atogepant)
pharmaquotient.com
-
17 August 2023
0
1
...
3
4
5
...
7
Page 4 of 7
Most Popular
Neuralink’s Blindsight: A Breakthrough in Vision Restoration
20 September 2024
Theratechnologies Indicated Potential Supply Disruption for EGRIFTA SV® in Early 2025
17 September 2024
Kissei Pharmaceuticals Enters into a Drug discovery research collaboration agreement with Reborna Biosciences.
9 September 2024
Takeda Receives European Commission Approval for ADZYNMA®▼ (Recombinant ADAMTS13) as the First and Only Recombinant ADAMTS13 Replacement Therapy for Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
7 September 2024
Load more
Recent Comments
Rahul
on
US FDA Approves Zurzuvae For Postpartum Depression
Rahul
on
JNJ Expands Cancer Portfolio with TALVEY Approval
Ashish
on
Flagship Pioneering Partners with Pfizer to Bolster Development of Innovative Medicine for $50M upfront
Recent Comments